scholarly journals Prevalence of Appendical Metastasis in Primary Surgery of Ovarian Epithelial Cancer

2020 ◽  
pp. 117-120
Author(s):  
Laila Nuranna ◽  
Jan H. Amili ◽  
Sigit Purbadi ◽  
Nessyah Fatahan
Keyword(s):  
Ovarian Cancer ◽  
Clinical Stage ◽  
Stage Iv ◽  
Cross Sectional Study ◽  
Stage Iii ◽  
Epithelial Cancer ◽  
Cross Sectional ◽  
Chronic Appendicitis ◽  
Primary Surgery ◽  
Ovarian Epithelial Cancer

Objective: To determine the prevalence of metastasis to appendix from primary surgery of ovarian epithelial cancer at National General Hospital Dr. Cipto Mangunkusumo (RSCM), Indonesia.Methods: A cross sectional study was done using ovarian epithelial cancer patient medical record whose primary ovarian cancer and appendectomy surgery were conducted on July to December 2019 at RSCM. Patients without appendix histopatology result and previous chemotherapy were excluded in this study. Consecutive method and random sampling were used in this study.Results: : A total of 80 subjects were included in this study. Subjects have average age of 48 years old. Out of all samples, 43 samples (53.8%) were defined as stage I patient, 7 subjects (8.8%) as stage II, 30 subjects (37.5%) as stage III, and none as stage IV. Appendectomy were done and eight subjects (10%) experienced metastasis to appendix. A total of 19 subjects (23.8%) had chronic appendicitis and 53 subjects (66.3%) did not have metastasis to the appendix. Among eight subjects having appendix involvement, 4 had mucinous histology, 2 serous, and 2 endometrioid. Six out of eight were diagnosed at clinical stage III and two were diagnosed at stage I.Conclusion: The prevalence of appendix metastases from primary surgery in ovarian epithelial cancer at RSCM was 10%. Based on this research, appendectomy can be considered on ovarian cancer surgeryKeywords:    appendix, metastasis, ovarian cancer.   Abstrak Tujuan: Mengetahui prevalensi metastasis kanker epitelial ovarium ke apendiks pada pembedahan primer kanker epitelial ovarium di Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (RSCM), Indonesia. Metode: Penelitian ini merupakan studi potong lintang menggunakan data rekam medis pasien kanker ovarium epitelial yang menjalani pembedahan primer dan apendiktomi pada bulan Juli hingga Desember 2019 di RSCM Pasien tanpa histopatologi apendiks atau pernah dilakukan kemoterapi sebelumnya dieksklusi dari penelitian. Digunakan metode pengambilan sampel secara acak. Hasil: Didapatkan 80 subjek penelitian yang diikutsertakan dalam penelitian. Dari 80 subjek penelitian, didapatkan rerata usia 48 tahun. Sebanyak 43 subjek (53,8%) didiagnosis dengan stadium I, 7 subjek (8,8%) sebagai stadium II, 30 subjek (37,5%) stadium III. Dari 80 subjek yang menjalani apendiktomi, didapatkan 8 subjek (10%) anak sebar ke apendiks, 19 subjek (23,8 %) apendisitis kronis, 53 subjek (66,3%) tidak terdapat anak sebar. Dari 8 subjek yang terdapat anak sebar ke apendiks dengan temuan histologi 4 musinosum, 2 serosum, 2 endometroid. Sebanyak enam dari delapan subjek terdiagnosis pada stadium klinis stadium III dan dua lainnya pada stadium klinis satu. Kesimpulan: Prevalensi metastasis apendiks pada operasi primer kanker ovarium epitelial di RSCM adalah sebesar 10%. Berdasarkan hasil penelitian ini, apendektomi dapat dipertimbangkan dilakukan pada pembedahan baik stadium awal maupun stadium lanjut.Kata kunci: , apendiks , kanker ovarium, metastatis

scholarly journals Experiencia Quirúrgica en el Manejo del Cáncer de Recto. Hospital de SOLCA, Guayaquil – Ecuador

2020 ◽  
Vol 12 (2) ◽  
pp. 92-97
Author(s):  
Carlos Humberto Malatay González ◽  
Juan Bernardo Pazmiño Palacios ◽  
Luis Andrés Idrovo Murillo ◽  
Jhónatan Miguel Siguencia Muñoz ◽  
Adriana Ximena Bravo Andrade
Keyword(s):  
Colorectal Cancer ◽  
Neoadjuvant Therapy ◽  
Clinical Stage ◽  
Cross Sectional Study ◽  
Histological Type ◽  
Stage Iii ◽  
Malignant Neoplasms ◽  
Advanced Clinical Stage ◽  
Cross Sectional ◽  
Common Histological Type

BACKGROUND: Colorectal cancer is the third most common among malignant neoplasms worldwide. Treatment choice depends on the location of the tumor, among other factors, and varies from local excision to abdominoperineal resection, adjuvant or neoadjuvant therapy can be needed, depending on clinical stage. The purpose of this study was to determine the most common histological type of rectal cancer, establish the most frequent clinical stage at diagnosis, the most common surgical technique and complications. METHODOLOGY: A cross-sectional study was carried out, with 160 patients treated in the digestive surgery service of Hospital SOLCA, Guayaquil – Ecuador, between January 2011 and December 2016, with colorectal cancer histologically diagnosed and treated surgically. RESULTS: Female sex was the most affected, with 65.7%, 63.1% of the patients were diagnosed at stage III, adenocarcinoma was the most common histological type (73.7%), the tumor was more frequently located at a low level, in 67.5% of the patients. Surgery was scheduled for 83.7% of the patients, derivative colostomy was the most common surgical procedure for treatment (48.8%), and the most common complications were those related to the ostomy, in 9.4% of the patients. Immediate mortality was 1.2% and late mortality was 8.1%. CONCLUSION: This study evidenced that colorectal cancer affected with more frequency to women, mainly to people over 60 years old. Most of the patients were diagnosed with advanced clinical stage (III) carcinoma, most frequently adenocarcinoma. Derivative colostomy was the procedure of choice for most of the patients, most of them needed neoadjuvant therapy too. The most common postsurgical complications were those related to ostomies.

A population registry trend analysis of neoadjuvant chemotherapy and incidence of ovarian, peritoneal and fallopian tube carcinomas in England 2004-2015.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17037-e17037
Author(s):  
Rebecca Elleray ◽  
Cong Chen ◽  
Sean Kehoe
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fallopian Tube ◽  
Stage Iv ◽  
Figo Stage ◽  
Stage Iii ◽  
Disease Stage ◽  
Primary Therapy ◽  
Peritoneal Cancer ◽  
Primary Surgery

e17037 Background: Two important developments in ovarian cancer have occurred over the last decade: i) EORTC 55971 and CHORUS trials reporting neoadjuvant chemotherapy as a management strategy in advanced disease and ii) recognition of fallopian tubes as the origin of many ovarian cancers. This study examines how these have impacted on care and registry data. Methods: The National Cancer Registry and Analysis Service (NCRAS) database identified women registered with ovarian, peritoneal and fallopian tube carcinomas during 2004-15. Treatment was defined as surgical intervention or chemotherapy starting within 6 months of diagnosis. Women were grouped into: Neoadjuvant chemotherapy, Primary surgery, Chemotherapy only, Surgery only or No record of therapy. Groups were analysed by year, FIGO stage and age. Results: 66,768 women were registered with an invasive carcinoma. Disease stage was not recorded in 44%. Of the remaining (n = 36,779) 32.1% stage I/II and 67.9% had stage III/IV disease. Of the 66,768 cases, 12.5 % had Neoadjuvant chemotherapy, 28.7% Primary surgery, 15.2% Surgery only, 19.7% Chemotherapy only and 23.2% No recorded therapy. Chemotherapy only was commonest at 36% in Stage IV, whereas primary surgery was in Stage III disease at 38%. No therapy was recorded in 11% and 25% of stage III and IV disease respectively. Neoadjuvant chemotherapy use trebled with time: comparing the rate in 2004-6 to 2013-15, there was an increase from7.7% to 21.7% ( p< 0.001). Those diagnosed with primary peritoneal cancer were significantly more likely ( p< 0.001) to have neoadjuvant chemotherapy compared to other groups. Cancers of the primary peritoneal and fallopian tube make up an increasing proportion of cases from 6% in 2004 to 13% in 2015. Conclusions: This is the largest reported study assessing trends in primary therapy and cases of ovarian, peritoneal and fallopian tube cancers during a time of novel developments. Neoadjuvant chemotherapy is becoming embedded in clinical practice. The reporting and analysis of ovarian cancer should include peritoneal and fallopian tube for consistent categorisation.

scholarly journals Prevalence and factors associated with pelvic organ prolapse among women attending the gynecology outpatient clinic at a tertiary hospital in southwestern Uganda

2021 ◽  
Author(s):  
RODGERS TUGUME ◽  
Henry Mark Lugobe ◽  
Paul Kalyebara Kato ◽  
Rogers Kajabwangu ◽  
Hamson Kanyesigye ◽  
...  
Keyword(s):  
Pelvic Organ Prolapse ◽  
Outpatient Clinic ◽  
Clinical Stage ◽  
Multiple Logistic Regression Analysis ◽  
Stage Iv ◽  
Tertiary Hospital ◽  
Pelvic Organ ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Factors Associated

Abstract Purpose To determine the prevalence, clinical stage at presentation and factors associated with pelvic organ prolapse (POP) among women attending the gynecology outpatient clinic at Mbarara Regional Referral Hospital (MRRH), Uganda. Methods We conducted a cross sectional study at the gynecology outpatient clinic of MRRH from September 2019 to January 2020. Multiple logistic regression analysis was done to determine factors associated with pelvic organ prolapse. Results Of 338 participants enrolled, the prevalence of POP was 27.5% (n = 93). POP stages were: stage I 11.8% (n = 11), stage II 63.4% (n = 59), stage III 16.1% (n = 15) and stage IV 8.9% (n = 8). Grand-multiparity (aOR 17.1, 95% CI: 1.1–66.6), birth weight more than 3.5kg (aOR 3.7, 95% CI: 1.1–12.6), perineal tears (aOR 6.5, 95% CI: 2.1–20.2), peasant farmer (aOR 6.9, 95% CI: 1.6–29.9) and duration of labour in the first delivery > 24 hours (aOR 5.7, 95% CI: 1.2–29) were significantly associated with POP.

scholarly journals Evaluation of sexual dysfunction in Brazilian women with breast cancer: partial results

Mastology ◽  
2020 ◽  
Vol 30 ◽  
Author(s):  
Letícia Barbosa Sposito ◽  
Caroline Nakano Vitorino ◽  
Vanildo Prado ◽  
Felipe Bedran ◽  
Jair Verginio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sexual Dysfunction ◽  
Clinical Stage ◽  
Stage Iv ◽  
Conservative Surgery ◽  
Cross Sectional Study ◽  
Sexual Performance ◽  
Cross Sectional ◽  
First Line Therapy ◽  
Student’S T

Objective: To assess the pattern of sexual performance in women treated for breast cancer. Methods: This is a cross-sectional study on women treated for breast cancer. Inclusion criteria: to have undergone the first-line therapy for cancer and the cancer not being classified as stage IV. Data on cancer were collected by the analysis of medical records. For the evaluation of sexual performance, women were submitted to individual interviews, with the application of the Quociente Sexual – Versão Feminina (QS F) questionnaire. Sexual performance was classified as: bad, unfavorable, regular, good, and excellent. The diagnosis of sexual dysfunction was established to women with score ≤ 60. For descriptive analyses, absolute (n) and relative (%) frequencies were performed, and for the comparison between the quantitative variables the Student’s t-test was used. Results: 31 women with a mean age of 55.2 years were included, 35% were classified as clinical stage II, 84% underwent conservative surgery, 65% underwent chemotherapy, and 80% used endocrinotherapy. Regarding sexual performance, 62% spontaneously think about sex, 35% are always interested in sex, and 51.7% have some degree of pain during intercourse. After calculating the score, it was concluded that 6.5% had bad sexual performance; 19.4%, unfavorable; 19.4%, regular; 41.9%, good; and 12.8%, excellent. The mean score was 58.7 points (standard deviation = 21.4, median of 64, minimum of 16, and maximum of 90 points), and 45.2% of women were diagnosed with sexual dysfunction. The provided treatments and the length of follow-up did not have a significant correlation with sexual performance. Conclusion: Most women treated for breast cancer had sexual performance classified as “good and excellent,” although a significant percentage had a diagnosis of sexual dysfunction.

scholarly journals Anemia and its determinants among TB-HIV co-infected adults of ART naïve in two public hospitals of Mekelle, Ethiopia: a facility based cross-sectional study

2019 ◽  
Author(s):  
Kebede Embaye Gezae ◽  
Kiflom Hagos Mebrahtu ◽  
Assefa Ayalew G/silasse
Keyword(s):  
Functional Status ◽  
Clinical Stage ◽  
Cross Sectional Study ◽  
Public Hospitals ◽  
Sub Saharan Africa ◽  
Stage Iii ◽  
Limited Information ◽  
Sectional Study ◽  
Advanced Clinical Stage ◽  
Cross Sectional

Abstract Background Anemia has up to 87% prevalence in high Tuberculosis (TB) and HIV burden settings of the Sub-Saharan Africa (SSA) including Ethiopia. It increases Lost to follow up (LTFU) rate, reduces quality of life and shortens the life expectancy of TB-HIV patients. Despite these facts, there is limited information on anemia and its determinants among TB-HIV adults of ART naïve in Ethiopia in general. Hence, the current study will partly fill the gap in the setting particularily.Methods A facility based cross-sectional study was conducted among 305 TB-HIV co-infected patients of ART naïve who have been started treatment from January, 2009 to December, 2017 in two public hospital of Mekelle, Ethiopia by reviewing an ART register and patient medical charts. A Generalized Linear Model (GLM) of binomial family with link function logit (logit model) was fitted to identify the statistically significant determinants of anemia. Finally, the decision was made based on the 95% Confidence Interval (95% CI) and the magnitude of association was measured based on the Adjusted Odds ratio (Adj. OR).Results At baseline, the cumulative prevalence of anemia was 59.0% (95% CI: 53.3% – 64.6%) where the prevalence of mild, moderate and severe anemia’s 24.6%, 28.2% and 6.2%, respectively. Female sex ((Adj.OR = 0.379; 95% CI: 0.226 – 0.635) and Body Mass Index (Adj. OR = 0.897, 95% CI: 0.823 - 0.977) reduces the odds of developing anemia whereas baseline ambulatory functional status (Adj. OR = 2.302; 95% CI: 1.293 - 4.097), Bedridden functional status (Adj. OR = 2.352; 95% CI: 1.074 - 5.149), HIV Clinical stage III (Adj. OR = 2.987; 95% CI: 1.226-7.279) and HIV Clinical stage IV (Adj. OR = 3.056; 95% CI: 1.219 - 7.657) increases the odds of anemia in TB-HIV co-infected adults of ART naïve in the current study.Conclusion Six in every ten TB-HIV co-infected adults of ART naïve developed anemia at baseline. Therefore, curious attention has to be given to undernourished, advanced clinical stage (III and IV) and non-working functional status TB-HIV adults to reducing anemia associated bad consequences.

scholarly journals Staging Parkinson’s Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life

2021 ◽  
Vol 2021 ◽  
pp. 1-16
Author(s):  
D. Santos García ◽  
T. De Deus Fonticoba ◽  
J. M. Paz González ◽  
C. Cores Bartolomé ◽  
L. Valdés Aymerich ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Stage ◽  
Stage Iv ◽  
Cross Sectional Study ◽  
Nonmotor Symptoms ◽  
Cross Sectional ◽  
Degenerative Disorder

Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage. Materials and Methods. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. Results. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB ( p < 0.0001 ). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively ( p < 0.005 ; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; p < 0.0001 ). Conclusion. The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.

Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5578-5578
Author(s):  
Matthew J. Monberg ◽  
Jennifer P Hall ◽  
Rebecca Moon ◽  
Olivia Higson ◽  
Kimmie McLaurin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Performance Status ◽  
Treatment Options ◽  
Advanced Ovarian Cancer ◽  
Stage Iv ◽  
Patient Characteristics ◽  
Cross Sectional Study ◽  
First Line ◽  
Cross Sectional ◽  
The Us

5578 Background: Bevacizumab (B) is approved in combination with carboplatin and paclitaxel, followed by B monotherapy, for the treatment of advanced ovarian cancer (OC) following surgery. We sought to describe B utilization and outcomes of B in first-line (1L) OC within the US and EU. Methods: This cross-sectional study included patients who were actively receiving treatment for OC. Data were collected at a single time point from 2496 patient forms between December 2017 and March 2018 from 340 oncologists/ gynecologists across the US, France, Germany, Italy, Spain, and the UK. Patients were platinum sensitive if progression was noted > 6 months after frontline platinum therapy and resistant if the interval was 0-6 months. This analysis included patients who received 1L chemotherapy (chemo) with no maintenance or 1L chemo with bevacizumab maintenance. Results: B was used in combination with chemo at 1L and as 1L maintenance monotherapy in 11% total study patients. Those receiving 1L + B were more likely to have Stage IV disease, have good performance status (PS) at diagnosis, and receive BRCA testing than patients receiving chemo only. Treatment response, platinum sensitivity, and activities of daily living are shown in the Table. Results did not vary by BRCA status. Conclusions: This study highlights differences in patient characteristics and outcomes between patients receiving/ who received 1L chemo only and those receiving/ who received B, however, this study was not designed to formally compare 1L treatment options. [Table: see text]

scholarly journals Early stage epithelial ovarian cancer metastasis through peritoneal fluid circulation

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Sigit Purbadi ◽  
Tricia Dewi Anggraeni ◽  
Angelina Vitria
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Peritoneal Fluid ◽  
Cancer Metastasis ◽  
Early Stage ◽  
Stage Iv ◽  
Cross Sectional Study ◽  
Surgical Staging ◽  
Cross Sectional ◽  
Peritoneal Tissue

Abstract Background Although epithelial ovarian cancer (EOC) spreads through peritoneal circulation, all patients with clinical early-stage ovarian cancer (OC) benefit from routine surgical staging is still unclear. Methods This cross-sectional study used data from medical records of patients with clinical early-stage EOC who received complete surgical staging from 2006 to 2016 at our hospital. We excluded patients with non-epithelial OC or with stage IV disease. Results Among 50 patients with clinical early-stage EOC who underwent surgical staging, biopsies showed EOC cells in peritoneal fluid for 12 patients (24%), in peritoneal tissue for ten patients (20%), and omental tissue for eight patients (16%). Of those 50 patients, 40 patients had undergone peritoneal biopsies, and the other five patients also had omental biopsies. The results showed that only one (2.5%) from 40 patients with peritoneal biopsy and three (6.7%) from 45 patients with omental biopsy had no visible nodules. From cytology examination, 3 out of 26 patients (11.5%) showed positive cytology from peritoneal washing. Conclusions Routine peritoneal biopsies do not seem advantageous for patients with clinical early-stage EOC as negative visible nodules with positive biopsy results were only 1 in 40 cases. However, further study with a larger cohort is needed to obtain more information on peritoneal fluid metastasis patterns.

Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer

1994 ◽  
Vol 4 (1) ◽  
pp. 66-71
Author(s):  
B. D. Evans ◽  
P. Chapman ◽  
P. Dady ◽  
G. Forgeson ◽  
D. Perez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Small Volume ◽  
Residual Disease ◽  
Stage Iv ◽  
Complete Response ◽  
Stage Ii ◽  
Stage Iii ◽  
Actuarial Survival ◽  
Moderate Volume ◽  
Grade Iii

Fifty-six patients with ovarian cancer (three stage IC, nine stage II, 33 stage III and II stage IV) were treated with carboplatin 350 mg m−2 i.v. day 1 and chlorambucil orally 0.15 mg kgm−1 days 1–7 inclusive, repeated every 28 days for eight courses. The regimen was well tolerated and was virtually free of nephro- and neurotoxicity. Grade III or IV hematology toxicity occurred in 18 patients but only 31 or 330 courses administered were delayed. Of 40 assessable patients eight achieved a clinical/radiologic complete response and 17 a clinical/radiologic partial response. Actuarial survival at 50 months was 65% for stage II patients, 27% for stage III patients and no stage IV patients survived beyond 20 months. Forty-two per cent of patients with residual disease less 2 cm survived 50 months, compared with 44% of patients with moderate volume (2–5 cm) residual disease and 6% of patients with bulk residual disease. This is an active, well tolerated regimen. However, only patients with small volume residual disease have a significant chance of prolonged survival.

Sign in / Sign up

Export Citation Format

Share Document